<DOC>
	<DOCNO>NCT02453672</DOCNO>
	<brief_summary>Pharmacokinetics , Safety , Tolerability , Immunogenicity Three Formulations Bevacizumab</brief_summary>
	<brief_title>Pharmacokinetic , Safety , Tolerability , Immunogenicity Study SB8 Healthy Male Subjects</brief_title>
	<detailed_description>A Randomised , Double-blind , Three-arm , Parallel Group , Single-dose Study Compare Pharmacokinetics , Safety , Tolerability , Immunogenicity Three Formulations Bevacizumab ( SB8 , EU Sourced Avastin® , US Sourced Avastin® ) Healthy Male Subjects</detailed_description>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Healthy male subject Have body weight 65.090.0 kg ( inclusive ) body mass index 20.029.9 kg/m2 ( inclusive ) Have history hypersensitivity allergic reaction bevacizumab excipients Have history and/or current clinically significant gastrointestinal , renal , hepatic , cardiovascular , haematological , pulmonary , neurologic , metabolic , psychiatric , allergic disease exclude mild asymptomatic seasonal allergy Have history arterial thromboembolic event include cerebrovascular accident , transient ischaemic attack , myocardial infarction Have history and/or current cardiac disease Have previously expose vascular endothelial growth factor ( VEGF ) antibody , antibody , protein target VEGF receptor Have history cancer include lymphoma , leukaemia , skin cancer . Have receive live vaccine ( ) within 30 day prior Screening visit require vaccine ( ) Screening end study visit Have take medication halflife &gt; 24 hour within 30 day 10 halflives medication prior IP administration</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>